share_log

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga Real-time News ·  May 16, 2022 20:24

 

Gainers

  • Athenex (NASDAQ:ATNX) shares increased by 30.5% to $0.62 during Monday's pre-market session. The market value of their outstanding shares is at $69.1 million. As per the press release, Q1 earnings came out 4 days ago.
  • Verastem (NASDAQ:VSTM) stock rose 25.0% to $1.35. The company's market cap stands at $251.5 million.
  • Cidara Therapeutics (NASDAQ:CDTX) stock increased by 14.48% to $0.49. The company's market cap stands at $33.8 million. The company's, Q1 earnings came out 3 days ago.
  • Genocea Biosciences (NASDAQ:GNCA) shares moved upwards by 13.33% to $0.26. The company's market cap stands at $14.9 million.
  • Phio Pharma (NASDAQ:PHIO) shares increased by 13.07% to $0.8. The market value of their outstanding shares is at $10.9 million. The company's, Q1 earnings came out 2 days ago.
  • Epizyme (NASDAQ:EPZM) shares increased by 11.4% to $0.58. The market value of their outstanding shares is at $95.6 million. As per the press release, Q1 earnings came out 4 days ago.

Losers

  • Chimerix (NASDAQ:CMRX) stock decreased by 52.6% to $2.01 during Monday's pre-market session. The company's market cap stands at $175.7 million. As per the press release, Q1 earnings came out today.
  • Valneva (NASDAQ:VALN) stock fell 19.39% to $20.08. The company's market cap stands at $1.0 billion.
  • Akebia Therapeutics (NASDAQ:AKBA) shares fell 16.52% to $0.38. The market value of their outstanding shares is at $68.8 million.
  • Immix Biopharma (NASDAQ:IMMX) stock fell 15.71% to $1.1. The company's market cap stands at $15.2 million.
  • Calithera Biosciences (NASDAQ:CALA) stock declined by 15.61% to $0.19. The company's market cap stands at $21.7 million. As per the press release, Q1 earnings came out 4 days ago.
  • Surgalign Holdings (NASDAQ:SRGA) stock fell 14.29% to $0.16. The company's market cap stands at $31.0 million. The company's, Q1 earnings came out 4 days ago. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment